A Clinical Study to Assess the Safety, In-use Tolerability of Test Product in Healthy Adult Subjects With Dry and Sensitive Skin.
Open-Label, Interventional, Prospective, Safety, In-Use Tolerability Study of Test Product "No Rays, Thanks Mineral Sunscreen" in Healthy Adult Subjects With Dry and Sensitive Skin.
1 other identifier
interventional
27
1 country
1
Brief Summary
This is open-label, interventional, prospective, safety in-use tolerability study of test product "No Rays, Thanks Mineral Sunscreen" in healthy adult human subjects with dry and sensitive skin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 28, 2024
CompletedFirst Posted
Study publicly available on registry
July 8, 2024
CompletedStudy Start
First participant enrolled
December 19, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 4, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 4, 2025
CompletedMarch 3, 2025
February 1, 2025
16 days
June 28, 2024
February 27, 2025
Conditions
Outcome Measures
Primary Outcomes (6)
Change in local intolerance assessment for skin irritation using 4-point scoring scale where 0 indicate absent and 3 indicate severe.
To assess the safety of the test product in terms of change in local intolerance assessment for irritation by dermatological assessment
On Day 01 at T15 minutes and on Day 15 (± 2 Days).
Change in local intolerance assessment for skin dryness using 4-point scoring scale where 0 indicate absent and 3 indicate severe.
To assess the safety of the test product in terms of change in local intolerance assessment for dryness by dermatological assessment
On Day 01 at T15 minutes and on Day 15 (± 2 Days).
Change in local intolerance assessment for skin oedema using 4-point scoring scale where 0 indicate absent and 3 indicate severe.
To assess the safety of the test product in terms of change in local intolerance assessment for oedema by dermatological assessment
On Day 01 at T15 minutes and on Day 15 (± 2 Days).
safety of the test product in terms of local intolerance assessment of irritation (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.
To evaluate the safety of the test product in terms of local intolerance assessment of irritation by Patient Global Assessment scale.
On Day 01 at T15 minutes and on Day 15 (± 2 Days).
safety of the test product in terms of local intolerance assessment of dryness (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.
To evaluate the safety of the test product in terms of local intolerance assessment of dryness by Patient Global Assessment scale.
On Day 01 at T15 minutes and on Day 15 (± 2 Days).
safety of the test product in terms of local intolerance assessment of oedema (Patient Global Assessment scale) where 0 indicate not at all and 10 indicate very severe.
To evaluate the safety of the test product in terms of local intolerance assessment of oedema by Patient Global Assessment scale.
On Day 01 at T15 minutes and on Day 15 (± 2 Days).
Secondary Outcomes (10)
where will you rank the test product in terms of appearance in which 1 indicate very poor and 5 indicate excellent.
On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)
where will you rank the test product in terms of spreadibility in which 1 indicate very poor and 5 indicate excellent.
On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)
where will you rank the test product in terms of texture in which 1 indicate very poor and 5 indicate excellent.
On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)
where will you rank the test product in terms of fragrance in which 1 indicate very poor and 5 indicate excellent.
On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)
where will you rank the test product in terms of absorption in which 1 indicate very poor and 5 indicate excellent.
On Day 01 and after test product usage on Day 01 at T15 minutes, and on Day 15 (±2 Days)
- +5 more secondary outcomes
Study Arms (1)
No Rays, Thanks Mineral sunscreen
EXPERIMENTALWash your face with standard facewash and apply a pea size amount on the face in the morning.
Interventions
Wash your face with standard facewash and apply a pea size amount on the face in the morning. Dosage form: semi-solid frequency: Once in a day Route of Administration: Topical
Eligibility Criteria
You may qualify if:
- Age: 18 to 55 years (both inclusive) at the time of consent.
- Sex: Healthy male and non-pregnant/non-lactating females. (Preferably equal ratio of males and females)
- Females of childbearing potential must have a self-reported negative pregnancy test.
- Subject are generally in good health.
- Subject with dry and sensitive skins. (As per the dermatological evaluation).
- Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
- If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- Subjects are willing to give written informed consent and are willing to come for regular follow up.
- Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study.
- Subject who have not participated in a similar investigation in the past three months.
- Willing to use test product throughout the study period.
You may not qualify if:
- History of any dermatological condition of the skin disease.
- Subject with present condition of allergic response to any cosmetic product.
- Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.
- History of alcohol or drug addiction.
- The subject has clinically significant skin disease, which may contraindicate participation, including psoriasis, eczema, skin cancer or other skin pathology.
- Subjects having skin infections like bacterial, fungal, viral infections.
- The subject has skin irritation, open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the face that can interfere with the reading.
- Be wearing any facial makeup, including false eyelashes, on the day of the study visit.
- Subjects having hypersensitive skin.
- Subjects using other marketed sun screen products during the study period.
- Pregnant or breastfeeding or planning to become pregnant during the study period.
- History of chronic illness which may influence the cutaneous state.
- Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- NovoBliss Research Pvt Ltdlead
- Kayura Effects LLPcollaborator
Study Sites (1)
NovoBliss Research Pvt.Ltd
Ahmedabad, Gujarat, 382481, India
Study Officials
- PRINCIPAL INVESTIGATOR
Dr. Nayan K Patel
NovoBliss Research Pvt Ltd
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 28, 2024
First Posted
July 8, 2024
Study Start
December 19, 2024
Primary Completion
January 4, 2025
Study Completion
January 4, 2025
Last Updated
March 3, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share